Physician profile
Bilal Saeed
NPI 1083878342
$6,341.47
in general payments reported to CMS, 2019-2025
23 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $11.32 · 2021: $51.83 · 2022: $1,227 · 2023: $2,159 · 2024: $2,290 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,629 · Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,629.19 |
| Food and Beverage | $1,058.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $4,384.59 | 2019-2025 | Impella |
| Medtronic, INC. | $907.62 | 2022-2023 | Corevalve Evolut R |
| Cardiovascular Systems INC. | $166.89 | 2019-2022 | |
| Abbott Laboratories | $160.10 | 2019 | |
| Amgen INC. | $96.08 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $79.09 | 2020-2025 | |
| Philips North America LLC | $75.05 | 2025 | Mechanical Tools |
| E.R. Squibb & Sons, L.L.C. | $46.90 | 2023-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $42.57 | 2022-2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $38.97 | 2024 | Arcalyst |
| Terumo Medical Corporation | $38.18 | 2019 | |
| Atricure, INC. | $37.57 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $36.96 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $33.33 | 2021 | |
| Baxter Healthcare | $30.89 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.66 | 2023 | Injectafer |
| Pfizer INC. | $25.69 | 2024 | |
| Janssen Pharmaceuticals, INC | $23.12 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.72 | 2024 | |
| Kestra Medical Technology Services, INC. | $21.32 | 2022 | |
| Shockwave Medical, INC | $17.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.45 | 2025 | Jardiance |
| Irhythm Technologies, INC. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.